Akèy › Myelom Miltip › Kalifòni › San Francisco
Etid klinik pou Myelom Miltip nan San Francisco, CA
15 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote San Francisco (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Ap rekriteFaz 1
- University of California San Francisco, San Francisco
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- University of California San Francisco, San Francisco
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Ap rekriteFaz 2
- University of California San Francisco, San Francisco
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Ap rekriteFaz 2
- University of California San Francisco, San Francisco
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Ap rekriteFaz 4
- University of California San Francisco, San Francisco
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- UCSF, San Francisco
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- Kaiser Permanente - South San Francisco Medical Center, San Francisco
- California Pacific Medical Center Research Institute, San Francisco
- Kaiser Permanente - San Francisco Medical Center, San Francisco
- ak 1 plis
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Ap rekriteFaz 1
- University of California, San Francisco, San Francisco
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 2
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- UCSF, San Francisco
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Ap rekriteFaz 1/2
- Research Site, San Francisco
Delayed Toxicities Post-CAR-T
Ap rekriteEtid obsèvasyon
- UCSF Medical Center, San Francisco
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Ap rekriteFaz 1
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- University of Calfornia, San Francisco, San Francisco
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO26 etid
- Columbus, OH24 etid
- Rochester, MN24 etid
- Baldwin Park, CA23 etid
- St. Louis, MO23 etid
- Washington, DC22 etid
Lòt etid nan San Francisco
- Kansè pwostat45 etid
- Kansè nan tete43 etid
- Kansè Poumon ki pa ti selil37 etid
- Kansè (tout kalite)35 etid
- Ensifizyans kadyak29 etid
- Kansè Metastatik29 etid
- Kansè poumon23 etid
- Melanom22 etid
- Kansè pankreyas20 etid
- Kansè kolorektal19 etid
- Maladi kadyovaskilè18 etid
- Gliyoblastòm18 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.